GSA Capital Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.25M | Buy |
9,877
+4,151
| +72% | +$547K | 0.08% | 376 |
|
|
2026
Q1 | $798K | Buy |
5,726
+3,851
| +205% | +$539K | 0.05% | 597 |
|
|
2025
Q4 | $230K | Sell |
1,875
-1,160
| -38% | -$141K | 0.02% | 1324 |
|
|
2025
Q3 | $337K | Buy |
+3,035
| New | +$345K | 0.03% | 1131 |
|
|
2024
Q2 | – | Sell |
-6,302
| Closed | -$462K | – | 1780 |
|
|
2024
Q1 | $462K | Buy |
+6,302
| New | +$485K | 0.04% | 933 |
|
|
2023
Q4 | – | Sell |
-3,603
| Closed | -$270K | – | 1653 |
|
|
2023
Q3 | $270K | Buy |
+3,603
| New | +$277K | 0.02% | 1136 |
|
|
2023
Q2 | – | Sell |
-2,719
| Closed | -$226K | – | 1650 |
|
|
2023
Q1 | $226K | Buy |
+2,719
| New | +$225K | 0.02% | 1194 |
|
|
2022
Q2 | – | Sell |
-7,468
| Closed | -$444K | – | 1542 |
|
|
2022
Q1 | $444K | Buy |
+7,468
| New | +$477K | 0.06% | 618 |
|
|
2021
Q4 | – | Sell |
-3,442
| Closed | -$240K | – | 1544 |
|
|
2021
Q3 | $240K | Buy |
+3,442
| New | +$242K | 0.02% | 1144 |
|
|
2021
Q2 | – | Sell |
-7,342
| Closed | -$475K | – | 1412 |
|
|
2021
Q1 | $475K | Buy |
+7,342
| New | +$473K | 0.08% | 386 |
|
|
2020
Q4 | – | Sell |
-9,014
| Closed | -$570K | – | 1344 |
|
|
2020
Q3 | $570K | Buy |
+9,014
| New | +$625K | 0.1% | 311 |
|
|
2020
Q1 | – | Sell |
-5,763
| Closed | -$374K | – | 1238 |
|
|
2019
Q4 | $374K | Sell |
5,763
-8,006
| -58% | -$521K | 0.04% | 856 |
|
|
2019
Q3 | $873K | Sell |
13,769
-4,608
| -25% | -$301K | 0.12% | 228 |
|
|
2019
Q2 | $1.24M | Sell |
18,377
-2,770
| -13% | -$182K | 0.14% | 151 |
|
|
2019
Q1 | $1.38M | Sell |
21,147
-2,178
| -9% | -$145K | 0.14% | 154 |
|
|
2018
Q4 | $1.46M | Buy |
23,325
+929
| +4% | +$64.9K | 0.17% | 110 |
|
|
2018
Q3 | $1.73M | Sell |
22,396
-20,216
| -47% | -$1.53M | 0.1% | 320 |
|
|
2018
Q2 | $3.02M | Sell |
42,612
-6,829
| -14% | -$482K | 0.15% | 111 |
|
|
2018
Q1 | $3.73M | Sell |
49,441
-51,563
| -51% | -$4.1M | 0.2% | 65 |
|
|
2017
Q4 | $7.24M | Buy |
101,004
+95,761
| +1,826% | +$7.27M | 0.44% | 4 |
|
|
2017
Q3 | $425K | Sell |
5,243
-5,696
| -52% | -$436K | 0.03% | 1060 |
|
|
2017
Q2 | $774K | Sell |
10,939
-16,156
| -60% | -$1.08M | 0.05% | 738 |
|
|
2017
Q1 | $1.84M | Sell |
27,095
-32,328
| -54% | -$2.27M | 0.1% | 294 |
|
|
2016
Q4 | $4.25M | Sell |
59,423
-7,176
| -11% | -$533K | 0.25% | 25 |
|
|
2016
Q3 | $5.27M | Buy |
66,599
+2,569
| +4% | +$209K | 0.28% | 20 |
|
|
2016
Q2 | $5.34M | Buy |
64,030
+13,147
| +26% | +$1.17M | 0.3% | 10 |
|
|
2016
Q1 | $4.67M | Sell |
50,883
-7,329
| -13% | -$661K | 0.3% | 10 |
|
|
2015
Q4 | $5.89M | Sell |
58,212
-35,098
| -38% | -$3.65M | 0.29% | 18 |
|
|
2015
Q3 | $9.16M | Buy |
93,310
+21,447
| +30% | +$2.38M | 0.45% | 13 |
|
|
2015
Q2 | $8.41M | Buy |
71,863
+27,259
| +61% | +$2.98M | 0.32% | 17 |
|
|
2015
Q1 | $4.38M | Buy |
44,604
+28,380
| +175% | +$2.88M | 0.17% | 75 |
|
|
2014
Q4 | $1.53M | Sell |
16,224
-35,893
| -69% | -$3.71M | 0.11% | 236 |
|
|
2014
Q3 | $5.55M | Buy |
+52,117
| New | +$5.1M | 0.29% | 60 |
|
|
2014
Q2 | – | Sell |
-108,679
| Closed | -$7.7M | – | 1862 |
|
|
2014
Q1 | $7.7M | Buy |
108,679
+96,262
| +775% | +$7.55M | 0.55% | 13 |
|
|
2013
Q4 | $933K | Sell |
12,417
-19,398
| -61% | -$1.35M | 0.07% | 409 |
|
|
2013
Q3 | $2M | Buy |
31,815
+26,525
| +501% | +$1.59M | 0.16% | 123 |
|
|
2013
Q2 | $271K | Buy |
+5,290
| New | +$276K | 0.03% | 932 |
|
Other funds holding GILD
GSA Capital Partners's GILD Position: Q2 2026 in Review
GSA Capital Partners increased its Gilead Sciences (GILD) stake by 72% in Q2 2026, buying an estimated $547K and bringing the position to 9,877 shares worth $1.25M. The position accounts for 0.08% of the portfolio, ranked #376.
GSA Capital Partners first reported a position in GILD in Q2 2013 and has held it in 37 quarters since. The position peaked at $9.16M in Q3 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- GSA Capital Partners held 9,877 shares of Gilead Sciences worth $1.25M as of Q2 2026.
- GSA Capital Partners bought 4,151 Gilead Sciences shares in Q2 2026, an estimated $547K.
- Gilead Sciences made up 0.08% of GSA Capital Partners's portfolio in Q2 2026, its #376 holding.
- GSA Capital Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 37 quarters since.
- GSA Capital Partners's Gilead Sciences position peaked at $9.16M in Q3 2015.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.